Revotar Biopharmaceuticals AG presents clinical data at the upcoming American Thoracic Society (ATS) International Conference:

“Phase II Multi-Center Trial With Inhaled Bimosiamose In Ambulatory Patients With Moderate To Severe COPD: Evaluation Of Dose Compliance”

Monday, February 20, 2012 - Revotar closes financing round.
Revotar received million € financing from existing shareholders and new investors.

BERLIN/Hennigsdorf (Germany), November 2nd, 2011   Revotar Biopharmaceuticals AG today announced that it has been granted a strategically important patent on a novel crystalline form of its pan-selectin antagonist Bimosiamose by the US Patent & Trademark Office (USPTO)....

download news

Positive multi-center COPD trial with inhaled Bimosiamose to be presented at the European Respiratory Society Annual Congress 2011 in Amsterdam

Data have been accepted for the late breaking news session at the upcoming annual congress of the European Respiratory Society (ERS) in Amsterdam and will be presented by the research group of Prof. Helgo Magnussen in an oral presentation Tuesday, September 27th during Session 460 (14:45-16:45, Forum).

download news

BERLIN/Hennigsdorf (Germany), May 18, 2011 – Revotar Biopharmaceuticals AG, a biotech company focusing on the development of small molecule anti-inflammatory drug candidates, today announced the final data (final TLFs) of its Phase II COPD study. The data confirm the already outlined positive top-line results released on March 30, 2011....

download news

Revotar Biopharmaceuticals meets primary endpoint in Phase II COPD Study with inhaled Bimosiamose

BERLIN/Hennigsdorf (Germany), March 04, 2011   Revotar Biopharmaceuticals AG today announced positive top-line results on a multi-center Phase II study to evaluate the safety and efficacy of inhaled Bimosiamose for the treatment of patients with chronic obstructive pulmonary disease (COPD).... read more

BERLIN/Hennigsdorf (Germany), June 10, 2010 – Revotar Biopharmaceuticals AG today announced the start of a Phase II study to evaluate the safety and efficacy of inhaled Bimosiamose, a pan-selectin antagonist, for the treatment of patients with chronic obstructive pulmonary disease (COPD).

download news

BERLIN/Hennigsdorf (Germany), May 18, 2010  -  Revotar Biopharmaceuticals AG today announced first positive results on a Phase IIa study conducted to evaluate the effect of Bimosiamose on ozone-induced  airway inflammation  in healthy subjects with a new controlled breathing nebulizer device.

download news

Berlin/Hennigsdorf  (Germany),  September  15,  2009  -  Revotar  Biopharmaceuticals  AG today announced that the company has been granted 2.5 million Euro from the German Federal State of Brandenburg  for  the development of its pipeline of selectin antagonists  in  respiratory indications.

download news  /  news in German

BERLIN/Hennigsdorf (Germany), July 3, 2009  - Revotar Biopharmaceuticals AG today announced the submission of a Phase IIa study to evaluate the effect of Bimosiamose on ozone-induced sputum neutrophilia in healthy subjects with a new controlled breathing nebulizer device.

download news /  news in German

Berlin/Hennigsdorf  (Germany),  June  03,  2009  - Revotar Biopharmaceuticals AG Announces the Appointment of Ludwig Felber as Chief Financial Officer and Member of the Executive Board and the Election of Prof Dr Wolfgang Hartwig as New Supervisory Board Member

download news /  news in German

HENNIGSDORF/BERLIN, GERMANY, Monday, September 22, 2008  – Revotar Biopharmaceuticals AG today announced the successful closing of its Series A financing round of 5.3 million EUR. Initially, the new investor IBG Risikokapitalfond I, which is managed by Goodvent Beteiligungsmanagement GmbH & Co KG, was joined by Deutsche Life Sciences GmbH and MVC Unternehmensbeteiligungsgesellschaft mbH. In a second closing, BFB BeteiligungsFonds Brandenburg GmbH came in as new investor and was joined by bmp AG.


download news  /  news in German